The prospect of regrowing lost teeth might soon become a reality. Toregem Biopharma, a Japanese pharmaceutical firm, is advancing with a pioneering tooth-regeneration drug, preparing it for clinical trials – a groundbreaking step for such medication.
Originating in Japan, Toregem Biopharma’s innovative drug is an antibody treatment designed to counteract proteins in the oral cavity that traditionally inhibit tooth development.
The inaugural human-centric clinical tests are set to commence in July 2024, indicating a bit of a wait before its practical implications are observed. As indicated by the Japan Times, if the clinical trials proceed favorably, the market could potentially see this drug by 2030.
The drug’s mechanism focuses on curbing the USAG-1 gene, which usually prevents “tooth buds” from evolving into either baby or adult teeth. Consequently, this gene acts as a barrier to the regeneration of teeth once they’re lost.
By nullifying this gene’s influence, researchers believe that the innovative drug can promote the proliferation of these buds. The implication is clear: patients may have the ability to regenerate missing teeth. Animal studies conducted in 2018 validated the drug’s efficacy in facilitating new tooth growth.
Toregem Biopharma is optimistic about launching a subsequent trial phase for the drug in 2025. This phase will cater to children aged 2 to 6 diagnosed with anodontia, a genetic condition hindering the emergence of their permanent teeth.
The outcomes of these trials carry significant weight, and it remains to be seen what the future holds for this pioneering drug.
